Sympagesic

1 x 100 ml

Liquid for injection, solution

Active substance

Metamizole (Metamizole sodium) : 500 mg/ml

Hyoscine / Scopolamine (Butylscopolaminebromide / Hyoscine butylbromide) : 4 mg/ml

ATC code

QA03DB04 Butylscopolamine and analgesics

QA03DB Belladonna and derivatives in comb. with analgesics

QA03D Antispasmodics in comb. with analgesics

QA03 Drugs for functional gastrointestinal disorders

QA Alimentary tract and metabolism

Species

Horses, cattle, pigs, dogs

Indications

Horses, cattle, pigs, dogs: treatment of smooth muscle spasms and pain associated with underlying disorders of the gastro-intestinal tract, urogenital system and bile excretory organs.

Horses only: Spasmodic colics.
Cattle, pigs, dogs: Supportive therapy for acute diarrhoea and gastroenteritis.

Dose to be administered and administration route

Horse: slow intravenous use
Pig: slow intravenous use or intramuscular use
single injection of 20 - 25 mg metamizole sodium monohydrate/kg body weight and 0.16 - 0.2 mg hyoscine butylbromide/kg body weight i.e. once 4 - 5 ml per 100 kg. For pigs, maximum injection volume is 5 mL per injection site.

Cattle: slow intravenous use or intramuscular use
Up to twice daily for three days, 20 - 25 mg metamizole sodium monohydrate/kg body weight and 0.16 - 0.2 mg hyoscine butylbromide/kg body weight i.e. 4 - 5 ml per 100 kg twice daily up to three days.

Dog: intravenous (slow) or intramuscular use,
single injection of 50 mg metamizole sodium monohydrate/kg body weight and 0.4 mg hyoscine butylbromide/kg body weight i.e. once 0.5 ml per 5 kg. Treatment can be repeated after 24 hours if necessary.

The stopper must not be punctured more than 25 times.

Adverse reactions

In very rare cases, anaphylactic reactions may occur and should be treated symptomatically.

In very rare cases, cardiovascular shock may occur if the intravenous injection is administered too fast.

In horses, mild tachycardia may be observed occasionally due to the parasympatholytic activity of hyoscine butylbromide.

In dogs painful reactions at the injection site can occur immediately after injection, which abate rapidly and have no negative impact on the expected therapeutic benefit.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).